GOTHENBURG, Sweden,
July 15, 2024 /PRNewswire/ --
Mölnlycke Health Care, a world-leading MedTech company specialising
in solutions for wound care and surgical procedures, announced
today an investment of US $15m in
MediWound Ltd. (Nasdaq: MDWD) (MediWound) through a definitive
share purchase agreement in a private investment in public equity
(PIPE). MediWound, a global leader in next-generation enzymatic
therapeutics focused on non-surgical wound debridement, has a
vision to improve the existing standards of care and patient
experiences, while reducing costs and unnecessary surgeries.
Debridement is a standard of care step to prepare the wound bed
for healing and can help in the management of infection. It
involves the removal of dead or devitalised tissue from a
wound.
"We are very excited to make this strategic investment in
MediWound. It aligns with our strategy to bring radical innovations
into the wound care space and provide alternative solutions to the
more traditional debridement options to improve clinical outcomes
and patient experience," said Zlatko Rihter, CEO of Mölnlycke.
"This investment will support Mölnlycke's Wound Care mission to
'help free patients from the burden of wounds' and I look forward
to this partnership."
Mölnlycke and MediWound have also entered into a collaboration
agreement to strengthen their partnership. Under the key terms of
this agreement, Mölnlycke is granted specific rights, including
having a representative attend meetings of MediWound's R&D
Committee and will also be able to participate in potential
strategic partnership discussions and M&A processes under
certain circumstances.
"We are delighted to have Mölnlycke's support. This substantial
investment will empower us to strengthen our strategic plans,
creating significant long-term value for our stakeholders and help
to improve standards of care for patients" said Ofer Gonen, CEO of MediWound.
For more information, please conatct:
Jennifer Doak
Global Communications Director Wound Care
Email: jennifer.doak@molnlycke.com
Phone: +1 678 206 6179
Ellie Hanson
FINN Partners for MediWound
Email: ellie.hanson@finnpartners.com
Phone: +1 929 588 2008
This information was brought to you by Cision
http://news.cision.com.
https://news.cision.com/molnlycke/r/molnlycke--health-care-announces-us--15m-investment-in-next-generation-enzymatic-therapeutics-compan,c4015001
The following files are available for download:
|
https://news.cision.com/molnlycke/i/molnlycke-primary-logotype-rgb,c3319952
|
Molnlycke-Primary-Logotype-rgb
|
View original
content:https://www.prnewswire.co.uk/news-releases/molnlycke-health-care-announces-us-15m-investment-in-next-generation-enzymatic-therapeutics-company-mediwound-ltd-302196800.html